Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Tetra Bio Pharma Inc T.TBP


Primary Symbol: TBPMQ

Tetra Bio-Pharma Inc. is a Canada-based cannabinoid-derived drug discovery and development company. The Company has developed a pipeline of cannabinoid-based drug products for a range of medical conditions, including pain, inflammation, and oncology. The Company has a pipeline of formulations and drug delivery systems with a portfolio of assets from the early research and development phase to advanced stage clinical programs. Its products include QIXLEEF, CAUMZ, PPP004, REDUVO, and REBORN 1. QIXLEEF is a botanical therapy with a fixed dosage of tetrahydrocannabinol (THC) and cannabidiol (CBD). CAUMZ is its inhaled cannabinoid-derived drug candidate. PPP004 is a topical preparation containing either a standardized amount of CBD or a defined ratio of THC and CBD. REDUVO is a soft gel capsule used to treat chemotherapy-induced nausea and vomiting (CINV) and weight loss and severe nausea in people living with human immunodeficiency virus (HIV) infection. REBORN 1 is in phase II trial.


GREY:TBPMQ - Post by User

Comment by Normandton Sep 20, 2022 2:33pm
109 Views
Post# 34974421

RE:RE:Reduvo

RE:RE:Reduvo Reduvo is already approved by the fda. On the Health Canada web site the same 10 drugs/products under review....at the top of the list are the same for around 6 months now....then there is no relation with TBP at all. //////////// Erwinia L-asparaginase Antineoplastic agents 2021-09 Porton Biopharma Limited Being reviewed under the Priority Review Policy Acetaminophen Analgesics 2021-04 B. Braun Melsungen AG Being reviewed under the Submissions Relying on Third-Party Data Guidance Bimatoprost Ophthalmologicals 2022-02 Aequus Pharmaceuticals Inc Being reviewed under the Submissions Relying on Third-Party Data Guidance Captopril Agents acting on the renin-angiotensin system 2021-04 Ethypharm Inc Being reviewed under the Submissions Relying on Third-Party Data Guidance Copper, manganese sulfate, selenious acid, sodium iodide, zinc sulfate Blood substitutes and perfusion solutions 2021-03 Sandoz Canada Incorporated Being reviewed under the Submissions Relying on Third-Party Data Guidance Dronabinol Antiemetics and antinauseants 2021-05 Tetra Bio-Pharma Inc. Being reviewed under the Submissions Relying on Third-Party Data Guidance Methotrexate Immunosuppressants 2022-05 Nordic Group B.V. Being reviewed under the Submissions Relying on Third-Party Data Guidance Methotrexate sodium Immunosuppressants 2021-11 Accord Healthcare Inc Being reviewed under the Submissions Relying on Third-Party Data Guidance Aflibercept Ophthalmologicals 2022-05 BGP Pharma ULC Biosimilar Bevacizumab
<< Previous
Bullboard Posts
Next >>